Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$89.51 USD
+0.69 (0.78%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $89.55 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.51 USD
+0.69 (0.78%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $89.55 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Zacks News
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $88.82, signifying a +0.6% move from its prior day's close.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Gilead Sciences (GILD) reachead $88.08 at the closing of the latest trading day, reflecting a -0.77% change compared to its last close.
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
by Zacks Equity Research
FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $87.23, denoting a -1.05% change from the preceding trading day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead, MRK Report Data From Investigational Combination Study for HIV
by Zacks Equity Research
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close.
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
by Zacks Equity Research
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
by Zacks Equity Research
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI